{"id":"sevelamer-carbonate","rwe":[],"_fda":{"id":"f4b7a1eb-7592-27f3-1316-50b7d2538cd1","set_id":"0085356d-5fec-3cce-2bd3-108be70e515d","openfda":{"unii":["9YCX42I8IU"],"route":["ORAL"],"rxcui":["749206"],"spl_id":["f4b7a1eb-7592-27f3-1316-50b7d2538cd1"],"brand_name":["Sevelamer Carbonate"],"spl_set_id":["0085356d-5fec-3cce-2bd3-108be70e515d"],"package_ndc":["55111-789-30","55111-789-90","55111-789-27","55111-789-48","55111-789-11"],"product_ndc":["55111-789"],"generic_name":["SEVELAMER CARBONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SEVELAMER CARBONATE"],"manufacturer_name":["DR. REDDY'S LABORATORIES LIMITED"],"application_number":["ANDA206094"],"is_original_packager":[true]},"version":"15","pregnancy":["8.1 Pregnancy Risk Summary Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology ( 12.2 )] . Consider supplementation. Data Animal data In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred in mid and high-dose groups (human equivalent doses approximately equal to 3 to 4 times the maximum clinical trial dose of 13 grams). In pregnant rabbits given oral doses of 100, 500 or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose)."],"overdosage":["10 OVERDOSAGE In CKD patients on dialysis, the maximum dose studied was 14 grams of sevelamer carbonate and 13 grams of sevelamer hydrochloride. There are no reports of overdosage with sevelamer carbonate or sevelamer hydrochloride in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low."],"description":["11 DESCRIPTION The active ingredient in sevelamer carbonate tablet is sevelamer carbonate, a polymeric amine that binds phosphate and is meant for oral administration. It was developed as a pharmaceutical alternative to sevelamer hydrochloride. Sevelamer carbonate is an anion exchange resin, with the same polymeric structure as sevelamer hydrochloride, in which carbonate replaces chloride as the counterion. While the counterions differ for the two salts, the polymer itself, the active moiety involved in phosphate binding, is the same. Sevelamer carbonate is known chemically as poly(allylamine-co-N,N’-diallyl-1,3-diamino-2-hydroxypropane) carbonate salt. Sevelamer carbonate is hygroscopic, but insoluble in water. The structure is represented in Figure 1. Figure 1. Chemical Structure of Sevelamer Carbonate a, b = number of primary amine groups a + b = 9 c = number of cross-linking groups c = 1 m = large number to indicate extended polymer network Sevelamer carbonate Tablets: Each film-coated tablet of sevelamer carbonate contains 800 mg of sevelamer carbonate on an anhydrous basis. The inactive ingredients are ammonium hydroxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, lecithin, mannitol, polyvinyl alcohol, propylene glycol, shellac, talc, xanthan gum and zinc stearate. The tablet imprint contains iron oxide black ink."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Tablets: Sevelamer carbonate Tablets 800 mg are supplied as white to off-white, oval, film-coated tablets plain on one side and imprinted ‘R789’ on other side, containing 800 mg of sevelamer carbonate on an anhydrous basis, ammonium hydroxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, lecithin, mannitol, polyvinyl alcohol, propylene glycol, shellac, talc, xanthan gum and zinc stearate. The tablet imprint contains iron oxide black ink. Bottles of 30 NDC 55111-789-30 Bottles of 90 NDC 55111-789-90 Bottles of 270 NDC 55111-789-27 Unit dose package of 100 (25 x 4) NDC 55111-789-11 Storage: Store at 20°-25°C (68°-77°F); [See USP Controlled Room Temperature] Protect from moisture."],"geriatric_use":["8.5 Geriatric Use Clinical studies of sevelamer carbonate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of sevelamer carbonate in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD. In this study, sevelamer carbonate was apparently less effective in children with a low baseline serum phosphorus, which described children <13 years of age and children not on dialysis. Given its mechanism of action, sevelamer carbonate is expected to be effective in lowering serum phosphorus levels in pediatric patients with CKD. Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate in the trial. Sevelamer carbonate tablets have not been studied in pediatric patients below 6 years of age."],"effective_time":"20250401","clinical_studies":["14 CLINICAL STUDIES The ability of sevelamer to control serum phosphorus in CKD patients on dialysis was predominantly determined from the effects of the hydrochloride salt to bind phosphate. Six clinical trials used sevelamer hydrochloride and two clinical trials used sevelamer carbonate. Thesevelamer hydrochloride studies include one double-blind, placebo controlled 2-week study (sevelamer N=24); two open-label, uncontrolled, 8-week studies (sevelamer N=220) and three active controlled open-label studies with treatment durations of 8 to 52 weeks (sevelamer N=256). The sevelamer carbonate studies include one double-blind, active-controlled, crossover study with two 8-week treatment periods using sevelamer carbonate tablets (N=79); and onerandomized, parallel, open-label study using sevelamer carbonate powder (N=144) dosed once daily or sevelamer hydrochloride tablets (N=73) dosed three times daily for 24 weeks. Five of the active-controlled studies are described here (two sevelamer carbonate and three sevelamer hydrochloride studies). 14.1 Cross-Over Study of Sevelamer Carbonate 800 mg and Sevelamer Hydrochloride 800 mg Stage 5 CKD patients on hemodialysis were entered into a five-week sevelamer hydrochloride run-in period and 79 patients received, in random order, sevelamer carbonate 800 mg tablets and sevelamer hydrochloride 800 mg tablets for eight weeks each, with no intervening washout. Study dose during the cross-over period was determined based on the sevelamer hydrochloride dose during the run-in period on a gram per gram basis. The phosphorus levels at the end of each of the two cross-over periods were similar. Average actual daily dose was 6 grams/day divided among meals for both treatments. Thirty-nine of those completing the cross-over portion of the study were entered into a two-week washout period during which patients were instructed not to take any phosphate binders; this confirmed the activity of sevelamer in this study. 14.3 Clinical Study of Sevelamer Carbonate Powder and Tablets in Pediatric Patients A clinical study with sevelamer carbonate was conducted in 101 patients 6 to 18 years of age with chronic kidney disease. This study included a washout period for patients on a phosphate binder, a 2-week, double-blind, fixed-dose period (FDP) in which patients were randomized to sevelamer carbonate (n=50) or placebo (n=51), and a 26-week, open-label, sevelamer carbonate dose titration period (DTP). Most patients were 13 to 18 years of age (73%) and had a BSA ≥1.2 m 2 (84%). Approximately 78% of patients were CKD patients on dialysis. Sevelamer carbonate significantly reduced serum phosphorus through Week 2 (primary endpoint) by an LS Mean difference of -0.90 (SE 0.27) mg/dL compared to placebo (p=0.001). A similar treatment response was observed in patients who received sevelamer carbonate during the 6-month open-label DTP. Approximately 30% of subjects reached their target serum phosphorus. The median prescribed daily dose was approximately 7.0 g per day during the titration period. The results of the primary efficacy endpoint were consistent by BSA subgroup. In contrast, a treatment effect was not observed in subjects with a baseline serum phosphorus below 7 mg/dL, many of whom were the subjects 6 to <13 years of age or the subjects not on dialysis (Figure 2). Figure 2: Change in Serum Phosphorus (mg/dL) from Baseline to Week 2 by Subgroup [a]: LS Mean difference of Sevelamer Carbonate – Placebo, based on ANCOVA within subgroup and with treatment as fixed effect and screening BSA and baseline serum phosphorus as covariates. 14.4 Sevelamer Hydrochloride versus Active-Control, Cross-Over Study in Hemodialysis Patients Eighty-four CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus > 6 mg/dL) following a two-week phosphate binder washout period were randomized in a cross-over design to receive in random order sevelamer hydrochloride and activecontrol for eight weeks each. Treatment periods were separated by a two-week phosphate binder washout period. Patients started on treatment three times per day with meals. Over each eight-week treatment period, at three separate time points the dose of sevelamer hydrochloride could be titrated up to control serum phosphorus, the dose of activecontrol could also be altered to attain phosphorus control. Both treatments significantly decreased mean serum phosphorus by about 2 mg/dL (Table 6). Table 6. Mean Serum Phosphorus (mg/dL) at Baseline and Endpoint Sevelamer Hydrochloride (N=81) Active Control (N=83) Baseline at End of Washout 8.4 8 Endpoint 6.4 5.9 Change from Baseline at Endpoint (95% Confidence Interval) -2* (-2.5, -1.5) -2.1* (-2.6, -1.7) *p<0.0001, within treatment group comparison The distribution of responses is shown in Figure 3. The distributions are similar for sevelamer hydrochloride and active control. The median response is a reduction of about 2 mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL. Figure 3. Percentage of Patients (Y-axis) Attaining a Phosphorus Reduction from Baseline (mg/dL) at Least as Great as the Value of the X-axis. Average daily sevelamer hydrochloride dose at the end of treatment was 4.9 grams (range of 0 to 12.6 grams). 14.5 Sevelamer Hydrochloride versus Active Control in Hemodialysis Patients Two hundred CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus > 5.5 mg/dL) following a two-week phosphate-binder washout period were randomized to receive sevelamer hydrochloride 800 mg tablets (N=99) or an activecontrol (N=101). At week 52, using last observation carried forward, sevelamer and active control both significantly decreased mean serum phosphorus (Table 7). Table 7. Mean Serum Phosphorus (mg/dL) and Ion Product at Baseline and Change from Baseline to End of Treatment Sevelamer HCl (N=94) Active-Control (N=98) Phosphorus Baseline Change from Baseline at Endpoint 7.5 -2.1 7.3 -1.8 Ca x Phosphorus Ion Product Baseline Change from Baseline at Endpoint 70.5 -19.4 68.4 -14.2 Sixty-one percent of sevelamer hydrochloride patients and 73% of the control patients completed the full 52 weeks of treatment. Figure 4, a plot of the phosphorus change from baseline for the completers, illustrates the durability of response for patients who are able to remain on treatment. Figure 4. Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment Average daily sevelamer hydrochloride dose at the end of treatment was 6.5 grams (range of 0.8 to 13 grams). 14.6 Sevelamer Hydrochloride versus Active-Control in Peritoneal Dialysis Patients One hundred and forty-three patients on peritoneal dialysis who were hyperphosphatemic (serum phosphorus>5.5 mg/dL) following a two-week phosphate binder washout period were randomized to receive sevelamer hydrochloride (N=97) or active control (N=46) open label for 12 weeks. Average daily sevelamer hydrochloride dose at the end of treatment was 5.9 grams (range 0.8 to 14.3 grams). Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active control group discontinued, mostly for gastrointestinal adverse reactions. There were statistically significant changes in serum phosphorus (p<0.001) for sevelamer hydrochloride (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to the active control. 14.7 Once-Daily versus Three-Times-Per-Day Dosing Stage 5 CKD patients on hemodialysis with a serum phosphate level of >5.5 mg/dL after washout from baseline therapies were randomized in a 2:1 ratio to receive either sevelamer carbonate powder once daily (N=144) or sevelamer hydrochloride as a tablet with the dose divided three-times-per-day (N=73) for 24 weeks. The initial dose for the two groups was 4.8 grams/day. At the end of the study, the total daily dose was 6.2 grams/day of sevelamer carbonate powder once daily and 6.7 grams/day of sevelamer hydrochloride tablets three-times-per-day. A greater percentage of subjects on the once daily dose than three-times-per-day regimen discontinued therapy prematurely, 35% versus 15%. The reasons for discontinuation were largely driven by adverse events and withdrawal of consent in the once daily dosing regimen. Serum phosphate levels and calcium-phosphate product were better controlled on the three times per day regimen than on the once daily regimen. Mean serum phosphorus decreased 2 mg/dL for sevelamer carbonate powder once daily and 2.9 mg/dL for sevelamer hydrochloride tablets three-times-per-day."],"pharmacodynamics":["12.2 Pharmacodynamics In addition to effects on serum phosphorus levels, sevelamer hydrochloride has been shown to bind bile acids in vitro and in vivo in experimental animal models. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat soluble vitamins such as A, D and K. In clinical trials of sevelamer hydrochloride, both the mean total and LDL cholesterol declined by 15% to 31% the clinical significance of this finding, which was observed after 2 weeks, is unclear. Triglycerides, HDL cholesterol, and albumin did not change."],"pharmacokinetics":["12.3 Pharmacokinetics A mass balance study using 14 C-sevelamer hydrochloride, in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed. No absorption studies have been performed in patients with renal disease. Drug Interactions In vivo Sevelamer carbonate has been studied in human drug-drug interaction studies (9.6 grams once daily with a meal) with warfarin and digoxin. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been studied in human drug-drug interaction studies (2.4 to 2.8 grams single dose or three times daily with meals or two times daily without meals) with ciprofloxacin, digoxin, enalapril, iron, metoprolol, mycophenolate mofetil, and warfarin. Coadministered single dose of 2.8 grams of sevelamer hydrochloride in fasted state decreased the bioavailability of ciprofloxacin by approximately 50% in healthy subjects. Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA C max and AUC 0-12h by 36% and 26% respectively. Sevelamer carbonate or sevelamer hydrochloride did not alter the pharmacokinetics of enalapril, digoxin, iron, metoprolol, and warfarin when coadministered. During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine. Reduction in concentrations of cyclosporine and tacrolimus leading to dose increases has also been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (for example, graft rejection). The possibility of an interaction cannot be excluded with these drugs."],"adverse_reactions":["6 ADVERSE REACTIONS Most of the safety experience is with sevelamer carbonate tablets and sevelamer hydrochloride. In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%) and constipation (8%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. There are limited clinical trial data on the safety of sevelamer carbonate. However, because it contains the same active ingredient as the hydrochloride salt, the adverse event profiles of the two salts are expected to be similar. In a cross-over study in hemodialysis patients with treatment durations of eight weeks each and no washout, and another cross-over study in hemodialysis patients, with treatment durations of four weeks each and no washout between treatment periods, the adverse reactions on sevelamer carbonate powder were similar to those reported for sevelamer hydrochloride. In a parallel design study of sevelamer hydrochloride with treatment duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride (n=99) were similar to those reported for the active-comparator group (n=101). Overall adverse reactions among those treated with sevelamer hydrochloride occurring in > 5% of patients included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%) and constipation (8%). A total of 27 patients treated with sevelamer and 10 patients treated with comparator withdrew from the study due to adverse reactions. Based on studies of 8 to 52 weeks, the most common reason for withdrawal from sevelamer hydrochloride was gastrointestinal adverse reactions (3% to 16%). In 143 peritoneal dialysis patients studied for 12 weeks using sevelamer hydrochloride, most common adverse reactions were similar to adverse reactions observed in hemodialysis patients. The most frequently occurring treatment emergent serious adverse reaction was peritonitis (8 reactions in 8 patients [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on active-control). Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active-control group discontinued, mostly for gastrointestinal adverse reactions. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride or sevelamer carbonate: hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, and uncommon cases of ileus, intestinal obstruction, and intestinal perforation. Appropriate medical management should be given to patients who develop constipation or have worsening of existing constipation to avoid severe complications."],"contraindications":["4 CONTRAINDICATIONS Sevelamer carbonate tablets are contraindicated in patients with bowel obstruction. Sevelamer carbonate tablets are contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. Bowel obstruction. ( 4 ) Known hypersensitivity to sevelamer carbonate,sevelamer hydrochloride, or to any of the excipients. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS There are no empirical data on avoiding drug interactions between sevelamer carbonate and most concomitant oral drugs. For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology ( 12.3 )]. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate release or an extended release product. Where possible consider monitoring clinical responses and/or blood levels of concomitant drugs that have a narrow therapeutic range. Table 5. Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Ciprofloxacin Mycophenolate mofetil Dosing Recommendations Take at least 2 hours before or 6 hours after sevelamer Take at least 2 hours before sevelamer • For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. ( 7 ) • Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin. ( 7 ) • Sevelamer has demonstrated interaction with ciprofloxacin, mycophenolate mofetil, and therefore these drugs should be dosed separately from sevelamer carbonate. ( 7 )"],"labor_and_delivery":["8.2 Lactation Risk Summary Sevelamer carbonate is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the child to sevelamer carbonate. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology ( 12.2 ) ]. Consider supplementation."],"mechanism_of_action":["12.1 Mechanism of Action Sevelamer carbonate tablet contains sevelamer carbonate, a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sevelamer carbonate tablet contains sevelamer carbonate, a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus). 12.2 Pharmacodynamics In addition to effects on serum phosphorus levels, sevelamer hydrochloride has been shown to bind bile acids in vitro and in vivo in experimental animal models. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat soluble vitamins such as A, D and K. In clinical trials of sevelamer hydrochloride, both the mean total and LDL cholesterol declined by 15% to 31% the clinical significance of this finding, which was observed after 2 weeks, is unclear. Triglycerides, HDL cholesterol, and albumin did not change. 12.3 Pharmacokinetics A mass balance study using 14 C-sevelamer hydrochloride, in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed. No absorption studies have been performed in patients with renal disease. Drug Interactions In vivo Sevelamer carbonate has been studied in human drug-drug interaction studies (9.6 grams once daily with a meal) with warfarin and digoxin. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been studied in human drug-drug interaction studies (2.4 to 2.8 grams single dose or three times daily with meals or two times daily without meals) with ciprofloxacin, digoxin, enalapril, iron, metoprolol, mycophenolate mofetil, and warfarin. Coadministered single dose of 2.8 grams of sevelamer hydrochloride in fasted state decreased the bioavailability of ciprofloxacin by approximately 50% in healthy subjects. Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA C max and AUC 0-12h by 36% and 26% respectively. Sevelamer carbonate or sevelamer hydrochloride did not alter the pharmacokinetics of enalapril, digoxin, iron, metoprolol, and warfarin when coadministered. During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine. Reduction in concentrations of cyclosporine and tacrolimus leading to dose increases has also been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (for example, graft rejection). The possibility of an interaction cannot be excluded with these drugs."],"indications_and_usage":["1 INDICATIONS AND USAGE Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate tablet is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. (1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. ( 5.1 ) 5.1 Gastrointestinal Adverse Events Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery were not included in the sevelamer carbonate clinical studies. Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention. Consider using sevelamer suspension in patients with a history of swallowing disorders. Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use [see Adverse Reactions ( 6.2 )] . Inflammatory disorders may resolve upon sevelamer discontinuation. Treatment with sevelamer should be re-evaluated in patients who develop severe gastrointestinal symptoms. 5.2 Reductions in Vitamins D, E, K (clotting factors) and Folic Acid Levels In preclinical studies in rats and dogs, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, reduced vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of 6 to 10 times the recommended human dose. In short-term clinical trials, there was no evidence of reduction in serum levels of vitamins. However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55 ng/mL) fell from 39 ± 22 ng/mL to 34 ± 22 ng/mL (p<0.01) with sevelamer hydrochloride treatment. Most (approximately 75%) patients in sevelamer hydrochloride clinical trials were receiving vitamin supplements."],"clinical_studies_table":["<table frame=\"border\" rules=\"all\"><tbody align=\"center\"><tr><td> </td><td><content styleCode=\"bold\">Sevelamer Hydrochloride</content><content styleCode=\"bold\">(N=81) </content></td><td><content styleCode=\"bold\">Active Control</content><content styleCode=\"bold\">(N=83) </content></td></tr><tr><td align=\"left\"> Baseline at End of Washout </td><td> 8.4 </td><td> 8 </td></tr><tr><td align=\"left\"> Endpoint </td><td> 6.4 </td><td> 5.9 </td></tr><tr><td align=\"left\"> Change from Baseline at Endpoint (95% Confidence Interval) </td><td> -2* (-2.5, -1.5) </td><td> -2.1* (-2.6, -1.7) </td></tr></tbody></table>","<table frame=\"border\" rules=\"all\"><tbody align=\"center\"><tr><td> </td><td><content styleCode=\"bold\">Sevelamer HCl</content> <content styleCode=\"bold\">(N=94) </content></td><td><content styleCode=\"bold\">Active-Control </content> <content styleCode=\"bold\"/><content styleCode=\"bold\">(N=98) </content></td></tr><tr><td align=\"left\"> Phosphorus  Baseline  Change from Baseline at Endpoint </td><td align=\"center\"> 7.5  -2.1 </td><td> 7.3  -1.8 </td></tr><tr><td align=\"left\"> Ca x Phosphorus Ion Product Baseline   Change from Baseline at Endpoint </td><td> 70.5  -19.4 </td><td> 68.4   -14.2 </td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 grams/kg/day. There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 13 grams). Mice received dietary administration of sevelamer hydrochloride at doses of up to 9 grams/kg/day (human equivalent dose 3 times the maximum clinical trial dose). There was no increased incidence of tumors observed in mice. In an in vitro mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in the Ames bacterial mutation assay. Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 grams/kg/day (human equivalent dose 3 times the maximum clinical trial dose of 13 grams)."],"drug_interactions_table":["<table frame=\"border\" rules=\"all\"><tbody><tr><td colspan=\"2\"><content styleCode=\"bold\">Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly </content></td></tr><tr><td colspan=\"2\">Digoxin  Enalapril  Iron  Metoprolol  Warfarin </td></tr><tr><td colspan=\"2\"><content styleCode=\"bold\">Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from </content><content styleCode=\"bold\">sevelamer carbonate </content></td></tr><tr><td>Ciprofloxacin  Mycophenolate mofetil </td><td><content styleCode=\"bold\">Dosing Recommendations </content> Take at least 2 hours before or 6 hours after sevelamer  Take at least 2 hours before sevelamer </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients to take sevelamer carbonate tablets with meals and adhere to their prescribed diets. For patients using an oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, advise the patient to take the oral medication at least one hour before or three hours after sevelamer carbonate. Advise patients to report new onset or worsening of existing constipation or bloody stools promptly to their physician [see Warnings and Precautions ( 5.1 )]. R X only Distributor: Dr. Reddy’s Laboratories Inc., Princeton NJ, 08540, USA Made in India Revised: 04/2025"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Starting dose of sevelamer carbonate tablet is 0.8 or 1.6 grams administered orally three times per day with meals based on serum phosphorus levels for adult patients and based on body surface area (BSA) category for pediatric patients ( 2.1 ) Titrate by 0.8 grams per meal in two week intervals for adult patients as needed to obtain serum phosphorus target. ( 2.1 ) Titrate based on BSA category for pediatric patients in two week intervals for 6 weeks and then every 4 weeks as needed to obtain serum phosphorus target. ( 2.1 ) 2.1 General Dosing Information Starting Dose for Adult Patients Not Taking a Phosphate Binder . The recommended starting dose of sevelamer carbonate tablets are 0.8 to 1.6 grams taken orally with meals based on serum phosphorus level. Table 1 provides recommended starting doses of sevelamer carbonate tablets for adult patients not taking a phosphate binder. Table 1. Starting Dose for Adult Dialysis Patients Not Taking a Phosphate Binder Serum Phosphorus Sevelamer Carbonate > 5.5 and < 7.5 mg/dL 0.8 grams three times daily with meals ≥ 7.5 mg/dL 1.6 grams three times daily with meals Dose Titration for Adult Patients Taking Sevelamer Carbonate Tablets . Titrate the sevelamer carbonate tablets dose by 0.8 grams three times per day with meals at two-week intervals as necessary to achieve target serum phosphorus levels. Based on clinical studies, the average prescribed adult daily dose of sevelamer carbonate is approximately 7.2 grams per day. The highest daily adult dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis. Starting Dose for Pediatric Patients Not Taking a Phosphate Binder. The recommended starting dose for pediatric patients 6 years of age and older is 0.8 to 1.6 grams taken three times per day with meals based on the patient’s body surface area (BSA) category; see Table 2. Table 2: Recommended Starting Dosage and Titration Increment Based on Pediatric Patient’s Body Surface Area (m 2 ) BSA (m 2 ) Starting Dose Per Meal/Snack Titration Increases/ Decreases Per Dose ≥0.75 to <1.2 0.8 grams Titrate by 0.4 grams ≥1.2 1.6 grams Titrate by 0.8 grams Dose Titration for Pediatric Patients Taking Sevelamer Carbonate Tablets . Titrate the sevelamer caronate dose as needed to achieve target levels at two-week intervals based on BSA category, as shown in Table 2. Switching from Sevelamer Hydrochloride Tablets . For adult patients switching from sevelamer hydrochloride tablets to sevelamer carbonate tablets or powder, use the same dose in grams. Switching between Sevelamer Carbonate Tablets and Powder . Use the same dose in grams. Switching from Calcium Acetate . Table 3 gives recommended starting doses of sevelamer carbonate tablets based on a patient’s current calcium acetate dose. Table 3. Starting Dose for Dialysis Patients Switching from Calcium Acetate to Sevelamer carbonate Tablets Calcium Acetate 667 mg (Tablets per meal) Sevelamer Carbonate 1 tablet 0.8 grams 2 tablets 1.6 grams 3 tablets 2.4 grams"],"spl_product_data_elements":["Sevelamer Carbonate Sevelamer Carbonate Sevelamer Carbonate Sevelamer Ammonia Silicon Dioxide Crospovidone HYDROXYPROPYL CELLULOSE (110000 WAMW) Lecithin, Soybean Mannitol Polyvinyl Alcohol Propylene Glycol Shellac Talc Xanthan Gum Zinc Stearate Ferrosoferric Oxide R789 white to off-white figure1 figure3 figure4 carton container Figure2"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets:800 mg white to off-white, oval, film-coated tablets plain on one side and imprinted ‘R789’ on other side. Tablets: : 800 mg (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology ( 12.2 )] . Consider supplementation. Data Animal data In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred in mid and high-dose groups (human equivalent doses approximately equal to 3 to 4 times the maximum clinical trial dose of 13 grams). In pregnant rabbits given oral doses of 100, 500 or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose). 8.2 Lactation Risk Summary Sevelamer carbonate is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the child to sevelamer carbonate. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology ( 12.2 ) ]. Consider supplementation. 8.4 Pediatric Use The safety and efficacy of sevelamer carbonate in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD. In this study, sevelamer carbonate was apparently less effective in children with a low baseline serum phosphorus, which described children <13 years of age and children not on dialysis. Given its mechanism of action, sevelamer carbonate is expected to be effective in lowering serum phosphorus levels in pediatric patients with CKD. Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate in the trial. Sevelamer carbonate tablets have not been studied in pediatric patients below 6 years of age. 8.5 Geriatric Use Clinical studies of sevelamer carbonate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range."],"dosage_and_administration_table":["<table frame=\"border\" rules=\"all\"><tbody><tr align=\"center\"><td><content styleCode=\"bold\">Serum Phosphorus</content></td><td><content styleCode=\"bold\">Sevelamer Carbonate</content></td></tr><tr align=\"center\"><td align=\"center\">&gt; 5.5 and &lt; 7.5 mg/dL</td><td align=\"center\">0.8 grams three times daily with meals</td></tr><tr align=\"left\"><td align=\"center\">&#x2265; 7.5 mg/dL</td><td align=\"center\">1.6 grams three times daily with meals</td></tr></tbody></table>","<table frame=\"border\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">BSA (m</content><content styleCode=\"bold\"><sup>2</sup></content><content styleCode=\"bold\">)</content></td><td align=\"center\"><content styleCode=\"bold\">Starting Dose Per </content> <content styleCode=\"bold\">Meal/Snack</content></td><td align=\"center\"><content styleCode=\"bold\">Titration Increases/</content> <content styleCode=\"bold\">Decreases Per Dose</content></td></tr><tr align=\"center\"><td align=\"center\">&#x2265;0.75 to &lt;1.2</td><td>0.8 grams</td><td>Titrate by 0.4 grams</td></tr><tr align=\"center\"><td>&#x2265;1.2</td><td>1.6 grams</td><td>Titrate by 0.8 grams</td></tr></tbody></table>","<table frame=\"border\" rules=\"all\"><tbody align=\"center\"><tr><td align=\"center\"><content styleCode=\"bold\">Calcium Acetate 667 mg</content><content styleCode=\"bold\">(Tablets per meal) </content></td><td align=\"center\"><content styleCode=\"bold\">Sevelamer Carbonate </content></td></tr><tr><td>1 tablet</td><td>0.8 grams</td></tr><tr><td>2 tablets</td><td>1.6 grams</td></tr><tr><td>3 tablets</td><td>2.4 grams</td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION Sevelamer Carbonate Tablets, 800 mg Container Label:","Sevelamer Carbonate Tablets, 800 mg Carton Label:"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 grams/kg/day. There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 13 grams). Mice received dietary administration of sevelamer hydrochloride at doses of up to 9 grams/kg/day (human equivalent dose 3 times the maximum clinical trial dose). There was no increased incidence of tumors observed in mice. In an in vitro mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in the Ames bacterial mutation assay. Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 grams/kg/day (human equivalent dose 3 times the maximum clinical trial dose of 13 grams)."]},"tags":[{"label":"Phosphate Binder","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Powder","category":"form"},{"label":"Tablet","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Renal Osteodystrophy with Hyperphosphatemia","category":"indication"},{"label":"Renal dialysis","category":"indication"},{"label":"Genzyme","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Chelating Agents","category":"pharmacology"},{"label":"Sequestering Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"2539 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1017 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"1006 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"810 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"676 reports"},{"date":"","signal":"END STAGE RENAL DISEASE","source":"FDA FAERS","actionTaken":"671 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"662 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"623 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"524 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"508 reports"}],"commonSideEffects":[{"effect":"Vomiting","drugRate":"22%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"20%","severity":"serious","_validated":true},{"effect":"Diarrhea","drugRate":"19%","severity":"serious","_validated":true},{"effect":"Dyspepsia","drugRate":"16%","severity":"serious","_validated":true},{"effect":"Abdominal pain","drugRate":"9%","severity":"common","_validated":true},{"effect":"Flatulence","drugRate":"8%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"8%","severity":"common","_validated":true},{"effect":"Peritonitis","drugRate":"8%","severity":"serious","_validated":true},{"effect":"Fecal impaction","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Ileus","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal obstruction","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal perforation","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute constipation","Dysphagia","Gastrointestinal hypomotility","Gastrointestinal obstruction","Gastroparesis","Hypophosphatemia","Operation on gastrointestinal tract","Vitamin D deficiency"],"specialPopulations":{"Pregnancy":"Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women. Consider supplementation.","Geriatric use":"Clinical studies of sevelamer carbonate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.","Paediatric use":"The safety and efficacy of sevelamer carbonate tablets in lowering serum phosphorus levels was studied in patients 5 years of age and older with CKD. In this study, sevelamer carbonate tablets was apparently less effective in children with low baseline serum phosphorus, which described children <13 years of age and children not on dialysis. Given its mechanism of action, sevelamer carbonate tablet is expected to be effective in lowering serum phosphorus levels in pediatric patients."}},"trials":[],"aliases":[],"company":"Sanofi","patents":[{"applNo":"N022318","source":"FDA Orange Book","status":"Active","expires":"Dec 6, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9095509","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.2404/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$88","description":"SEVELAMER CARBONATE 800 MG TAB","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SEVELAMER CARBONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:40:44.369671+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:40:44.369183+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:40:50.223141+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:40:44.389461+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:40:42.975626+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SEVELAMER CARBONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:40:51.006112+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:40.964313+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:40.964374+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:40:52.933646+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314347/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:51.891602+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA206094","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:40.964385+00:00"}},"allNames":"renvela","offLabel":[],"synonyms":["sevelamer carbonate","renvela"],"timeline":[{"date":"2007-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GENZYME to Genzyme"},{"date":"2007-10-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genzyme)"},{"date":"2009-06-09","type":"positive","source":"DrugCentral","milestone":"EMA approval (Genzyme Europe Bv)"},{"date":"2023-04-19","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 16 manufacturers approved"}],"aiSummary":"Renvela, also known as Sevelamer Carbonate, is a small molecule medication. It is used to treat conditions such as obesity-related glomerulopathy, chronic kidney disease, chronic kidney failure, and hyperphosphatemia.","approvals":[{"date":"2007-10-19","orphan":false,"company":"GENZYME","regulator":"FDA"},{"date":"2009-06-09","orphan":false,"company":"GENZYME EUROPE BV","regulator":"EMA"}],"brandName":"Renvela","ecosystem":[{"indication":"Renal Osteodystrophy with Hyperphosphatemia","otherDrugs":[{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"lanthanum carbonate","slug":"lanthanum-carbonate","company":"Shire Llc"},{"name":"sevelamer","slug":"sevelamer","company":""}],"globalPrevalence":null},{"indication":"Renal dialysis","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"moaClass":"Phosphate Chelating Activity","modality":"Small Molecule","drugClass":"Phosphate Binder","explanation":"Sevelamer carbonate tablets contains sevelamer carbonate, non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus).","oneSentence":"Renvela works by binding to dietary phosphate in the gut, preventing its absorption into the bloodstream.","technicalDetail":"Sevelamer carbonate is a polyvalent cationic exchange resin that binds to dietary phosphate in the gastrointestinal tract through ionic exchange, thereby reducing phosphate absorption and serum phosphate levels."},"commercial":{"launchDate":"2007","_launchSource":"DrugCentral (FDA 2007-10-19, GENZYME)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4331","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SEVELAMER%20CARBONATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SEVELAMER CARBONATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:37:20.255161","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:58.002353+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"sevelamer carbonate","indications":{"approved":[{"name":"Renal Osteodystrophy with Hyperphosphatemia","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"adults and children 5 years of age and older with chronic kidney disease (CKD) on dialysis"},{"name":"Renal dialysis","source":"DrugCentral","snomedId":265764009,"regulator":"FDA","eligibility":"adults and children 5 years of age and older with chronic kidney disease (CKD) on dialysis"}],"offLabel":[],"pipeline":[]},"currentOwner":"Genzyme","drugCategory":"mature","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07030595","phase":"PHASE3","title":"AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Alebund Pharmaceuticals","startDate":"2023-06-12","conditions":["ESRD (End Stage Renal Disease)","Chronic Kidney Disease(CKD)","Hyperphosphatemia","Hyperphosphatemia in Chronic Kidney Disease","Dialysis","Chronic Kidney Disease, Receiving Dialysis"],"enrollment":474,"completionDate":"2025-05-30"},{"nctId":"NCT01220843","phase":"PHASE3","title":"FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-10","conditions":["Chronic Renal Failure"],"enrollment":98,"completionDate":"2013-04"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT06664125","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-12-30","conditions":["Hyperphosphatemia"],"enrollment":50,"completionDate":"2025-09-30"},{"nctId":"NCT04485039","phase":"PHASE4","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-06-08","conditions":["Smallpox"],"enrollment":44,"completionDate":"2023-04-23"},{"nctId":"NCT06660524","phase":"PHASE4","title":"Calcium-Phosphorus Regulation Therapy on Heart Valve Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-03-01","conditions":["Degenerative Heart Valve Disease","Heart Valve Calcification","Chronic Kidney Disease(CKD)","Calcium-Phosphorus Metabolism Disorders"],"enrollment":196,"completionDate":"2025-12"},{"nctId":"NCT04456803","phase":"PHASE3","title":"Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Sinomune Pharmaceutical Co., Ltd","startDate":"2019-05-24","conditions":["Hyperphosphatemia","End Stage Renal Disease","ESRD"],"enrollment":239,"completionDate":"2022-09-13"},{"nctId":"NCT05764590","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients","status":"COMPLETED","sponsor":"Alebund Pharmaceuticals","startDate":"2023-02-20","conditions":["Chronic Kidney Diseases","Hyperphosphatemia"],"enrollment":55,"completionDate":"2023-09-14"},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":["Adenovirus","Anesthesia","Anxiety","Anxiolysis","Autism","Autistic Disorder","Bacterial Meningitis","Bacterial Septicemia","Benzodiazepine","Bipolar Disorder","Bone and Joint Infections","Central Nervous System Infections","Convulsions","Cytomegalovirus Retinitis","Early-onset Schizophrenia Spectrum Disorders","Epilepsy","General Anesthesia","Gynecologic Infections","Herpes Simplex Virus","Infantile Hemangioma","Infection","Inflammation","Inflammatory Conditions","Intra-abdominal Infections","Lower Respiratory Tract Infections","Migraines","Pain","Pneumonia","Schizophrenia","Sedation","Seizures","Skeletal Muscle Spasms","Skin and Skin-structure Infections","Treatment-resistant Schizophrenia","Urinary Tract Infections","Withdrawal","Sepsis","Gram-negative Infection","Bradycardia","Cardiac Arrest","Cardiac Arrhythmia","Staphylococcal Infections","Nosocomial Pneumonia","Neuromuscular Blockade","Methicillin Resistant Staphylococcus Aureus","Endocarditis","Neutropenia","Headache","Fibrinolytic Bleeding","Pulmonary Arterial Hypertension","CMV Retinitis","Hypertension","Chronic Kidney Diseases","Hyperaldosteronism","Hypokalemia","Heart Failure","Hemophilia","Heavy Menstrual Bleeding","Insomnia"],"enrollment":3520,"completionDate":"2019-11"},{"nctId":"NCT03427125","phase":"PHASE3","title":"A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2018-01-08","conditions":["Hyperphosphatemia"],"enrollment":1559,"completionDate":"2020-02-27"},{"nctId":"NCT00999037","phase":"NA","title":"FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-10","conditions":["Secondary Hyperparathyroidism"],"enrollment":18,"completionDate":"2015-06"},{"nctId":"NCT03988920","phase":"PHASE4","title":"A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2019-06-15","conditions":["Hyperphosphatemia","End Stage Renal Disease"],"enrollment":172,"completionDate":"2021-07-31"},{"nctId":"NCT03824587","phase":"PHASE2,PHASE3","title":"Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2019-02-28","conditions":["Hyperphosphatemia"],"enrollment":236,"completionDate":"2019-07-17"},{"nctId":"NCT04551300","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Shanghai Alebund Pharmaceuticals Limited","startDate":"2020-10-13","conditions":["Hyperphosphatemia"],"enrollment":158,"completionDate":"2022-10-15"},{"nctId":"NCT03001011","phase":"PHASE3","title":"Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-06-07","conditions":["Hyperphosphatemia"],"enrollment":202,"completionDate":"2019-08-16"},{"nctId":"NCT04120922","phase":"NA","title":"Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-01-07","conditions":["Chronic Kidney Diseases"],"enrollment":21,"completionDate":"2022-04"},{"nctId":"NCT03451019","phase":"PHASE4","title":"Different Effects of Non-calcium Phosphate Binders on Serum Calcium","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2018-03-01","conditions":["Chronic Kidney Disease"],"enrollment":34,"completionDate":"2020-12-30"},{"nctId":"NCT00151918","phase":"PHASE3","title":"Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-07","conditions":["Kidney Failure, Chronic"],"enrollment":48,"completionDate":"2005-08-22"},{"nctId":"NCT00875017","phase":"PHASE1","title":"Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-04-20","conditions":["Kidney Failure, Chronic"],"enrollment":31,"completionDate":"2009-06-16"},{"nctId":"NCT00925704","phase":"PHASE1","title":"The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-06-01","conditions":["Healthy"],"enrollment":41,"completionDate":"2009-07-31"},{"nctId":"NCT00441545","phase":"PHASE3","title":"Head to Head Study Against Sevelamer Hydrochloride","status":"COMPLETED","sponsor":"Shire","startDate":"2007-01-05","conditions":["Chronic Kidney Disease, Stage 5"],"enrollment":182,"completionDate":"2008-07-31"},{"nctId":"NCT03644264","phase":"PHASE3","title":"PA21 Safety and Efficacy in Adult Chinese Subjects","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2018-08-31","conditions":["Chronic Kidney Disease Requiring Chronic Dialysis","Hyperphosphatemia"],"enrollment":286,"completionDate":"2020-08-21"},{"nctId":"NCT03984760","phase":"PHASE3","title":"Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Panion & BF Biotech Inc.","startDate":"2019-06-19","conditions":["Hyperphosphatemia","End Stage Renal Disease","ESRD"],"enrollment":240,"completionDate":"2021-02-20"},{"nctId":"NCT04299633","phase":"PHASE1","title":"Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-06-15","conditions":["Healthy Volunteers"],"enrollment":54,"completionDate":"2020-09-28"},{"nctId":"NCT00745589","phase":"NA","title":"Sevelamer Hydrochloride in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-07","conditions":["Endstage Renal Disease"],"enrollment":60,"completionDate":"2015-01"},{"nctId":"NCT03305471","phase":"PHASE1","title":"DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-08-17","conditions":["Hyperphosphatemia"],"enrollment":40,"completionDate":"2019-01-03"},{"nctId":"NCT01543958","phase":"PHASE2","title":"Sevelamer for Reducing Endotoxemia and Immune Activation","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":["HIV-1 Infection"],"enrollment":40,"completionDate":"2012-11"},{"nctId":"NCT02644486","phase":"NA","title":"A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy","status":"TERMINATED","sponsor":"Zhi-Hong Liu, M.D.","startDate":"2016-01","conditions":["Obesity and Glomerulopathy"],"enrollment":4,"completionDate":"2018-02"},{"nctId":"NCT02965053","phase":"PHASE1","title":"A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2016-12","conditions":["Hyperphosphatemia"],"enrollment":26,"completionDate":"2018-08"},{"nctId":"NCT03596749","phase":"PHASE3","title":"The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4","status":"UNKNOWN","sponsor":"Fan Fan Hou","startDate":"2018-09-01","conditions":["CKD Stage 3b","CKD Stage 4"],"enrollment":80,"completionDate":"2019-07-01"},{"nctId":"NCT01308242","phase":"EARLY_PHASE1","title":"Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2011-03","conditions":["Chronic Kidney Disease"],"enrollment":40,"completionDate":"2014-02-27"},{"nctId":"NCT02684643","phase":"NA","title":"Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2016-01","conditions":["Hyperphosphatemia","End-stage Renal Disease"],"enrollment":72,"completionDate":"2017-04"},{"nctId":"NCT01238588","phase":"NA","title":"The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2011-06-10","conditions":["Dialysis","Cardiovascular Disease","Atherosclerosis","Inflammation","Hyperphosphatemia"],"enrollment":24,"completionDate":"2016-04-08"},{"nctId":"NCT03202407","phase":"PHASE3","title":"Hyperphosphatemia in Children With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-01","conditions":["Hyperphosphatemia"],"enrollment":40,"completionDate":"2018-12-01"},{"nctId":"NCT02332811","phase":"PHASE3","title":"An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2013-10","conditions":["Renal Failure Chronic"],"enrollment":96,"completionDate":"2014-07"},{"nctId":"NCT01191762","phase":"PHASE3","title":"Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Kenneth R. Phelps, M.D.","startDate":"2010-04","conditions":["Hyperparathyroidism","Chronic Kidney Disease"],"enrollment":30,"completionDate":"2013-04"},{"nctId":"NCT01574326","phase":"PHASE2","title":"An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2012-05","conditions":["Hyperphosphatemia","Chronic Kidney Disease"],"enrollment":101,"completionDate":"2015-06"},{"nctId":"NCT02822131","phase":"NA","title":"Phosphate in Blood Pressure Regulation","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-01","conditions":["Hypertension"],"enrollment":10,"completionDate":"2016-06"},{"nctId":"NCT01011699","phase":"PHASE3","title":"Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-01","conditions":["Chronic Renal Failure","Hemodialysis"],"enrollment":176,"completionDate":"2013-06"},{"nctId":"NCT01277497","phase":"PHASE4","title":"Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4","status":"TERMINATED","sponsor":"Albany College of Pharmacy and Health Sciences","startDate":"2011-01","conditions":["Chronic Kidney Disease"],"enrollment":30,"completionDate":"2016-03"},{"nctId":"NCT01427907","phase":"PHASE4","title":"Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients","status":"COMPLETED","sponsor":"Fresenius Medical Care North America","startDate":"2011-09","conditions":["Chronic Kidney Disease"],"enrollment":38,"completionDate":"2012-07"},{"nctId":"NCT01968759","phase":"PHASE2","title":"Sevelamer in Proteinuric CKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-10","conditions":["Chronic Kidney Disease"],"enrollment":53,"completionDate":"2015-10"},{"nctId":"NCT00853242","phase":"PHASE2","title":"Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-02","conditions":["Kidney Failure, Chronic"],"enrollment":349,"completionDate":"2009-08"},{"nctId":"NCT00833768","phase":"PHASE3","title":"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-01","conditions":["Chronic Kidney Disease","Hyperphosphatemia"],"enrollment":5,"completionDate":"2009-09"},{"nctId":"NCT01857024","phase":"","title":"Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-09","conditions":["Hyperphosphataemia","Chronic Kidney Disease"],"enrollment":210,"completionDate":"2012-10"},{"nctId":"NCT01736150","phase":"PHASE3","title":"Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-03","conditions":["Chronic Kidney Disease","Chronic Kidney Disease on Hemodialysis"],"enrollment":205,"completionDate":"2010-09"},{"nctId":"NCT00681941","phase":"PHASE3","title":"An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-01","conditions":["Chronic Kidney Disease","Hyperphosphatemia"],"enrollment":49,"completionDate":"2007-03"},{"nctId":"NCT00267514","phase":"PHASE3","title":"Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-01","conditions":["Chronic Kidney Disease"],"enrollment":31,"completionDate":"2007-05"},{"nctId":"NCT02346890","phase":"PHASE1","title":"A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2013-04","conditions":["Healthy"],"enrollment":16,"completionDate":"2013-04"},{"nctId":"NCT01191255","phase":"PHASE3","title":"A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis","status":"COMPLETED","sponsor":"Keryx Biopharmaceuticals","startDate":"2010-10","conditions":["Hyperphosphatemia","Kidney Failure"],"enrollment":441,"completionDate":"2013-02"},{"nctId":"NCT01755078","phase":"PHASE4","title":"Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2007-06","conditions":["Hemodialysis","Hyperphosphatemia","Cardiovascular Events"],"enrollment":166,"completionDate":"2009-06"},{"nctId":"NCT01324128","phase":"PHASE3","title":"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-03","conditions":["Chronic Kidney Disease Requiring Chronic Dialysis"],"enrollment":1059,"completionDate":"2012-10"},{"nctId":"NCT01493050","phase":"PHASE2","title":"The Effects of Sevelamer Carbonate on Diabetic Nephropathy","status":"COMPLETED","sponsor":"Gary Striker","startDate":"2012-02","conditions":["Diabetic Nephropathy"],"enrollment":117,"completionDate":"2013-12"},{"nctId":"NCT01464190","phase":"PHASE3","title":"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-09","conditions":["Chronic Kidney Disease Requiring Chronic Dialysis"],"enrollment":659,"completionDate":"2013-04"},{"nctId":"NCT00268957","phase":"PHASE3","title":"Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-01","conditions":["Kidney Diseases","Chronic Renal Insufficiency","End-Stage Renal Disease"],"enrollment":217,"completionDate":"2007-05"},{"nctId":"NCT00440648","phase":"PHASE2","title":"Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-03","conditions":["Chronic Kidney Disease"],"enrollment":80,"completionDate":"2006-07"},{"nctId":"NCT01799317","phase":"PHASE4","title":"How Bone is Made in Children Receiving Dialysis","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2009-03","conditions":["Bone Mineralization Defect"],"enrollment":60,"completionDate":"2014-06"},{"nctId":"NCT00710788","phase":"NA","title":"Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis","status":"COMPLETED","sponsor":"Azienda Sanitaria ASL Avellino 2","startDate":"2007-01","conditions":["Cardiovascular Mortality"],"enrollment":360,"completionDate":"2011-09"},{"nctId":"NCT00785629","phase":"NA","title":"A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD","status":"COMPLETED","sponsor":"Denver Nephrologists, P.C.","startDate":"2009-02","conditions":["Chronic Kidney Disease"],"enrollment":148,"completionDate":"2011-07"},{"nctId":"NCT00837655","phase":"NA","title":"Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)","status":"WITHDRAWN","sponsor":"Karolinska Institutet","startDate":"2009-01","conditions":["Kidney Failure, Chronic","End-Stage Renal Disease","Insulin Resistance","Hyperphosphatemia"],"enrollment":0,"completionDate":"2011-06"},{"nctId":"NCT00806481","phase":"PHASE2","title":"Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2009-02","conditions":["Kidney Failure, Chronic","Cardiovascular Diseases"],"enrollment":120,"completionDate":"2011-10"},{"nctId":"NCT00967629","phase":"PHASE1","title":"Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2009-06","conditions":["Diabetic Nephropathy"],"enrollment":20,"completionDate":"2010-02"},{"nctId":"NCT01049815","phase":"NA","title":"Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2005-02","conditions":["End Stage Renal Disease","Hemodialysis","Intimal Media Thickness"],"enrollment":175,"completionDate":"2009-02"},{"nctId":"NCT00560300","phase":"PHASE2","title":"Regulation of Bone Formation in Renal Osteodystrophy","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-11","conditions":["Secondary Hyperparathyroidism","Renal Osteodystrophy"],"enrollment":61,"completionDate":"2006-11"}],"_emaApprovals":[{"date":"2009-06-09","status":"Authorised","company":"GENZYME EUROPE BV"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Powder, Tablet","formulations":[{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"SEVELAMER CARBONATE"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Sevelamer Carbonate"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Sevelamer Carbonate For Oral Suspension"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Sevelamer Carbonate for Oral Suspension"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"sevelamer carbonate"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Renvela"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Sevelamer Carbonate"},{"form":"TABLET","route":"ORAL","productName":"SEVELAMER CARBONATE"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"SEVELAMER CARBONATE"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Sevelamer Carbonate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Sevelamer carbonate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Renvela"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Sevelamer Carbonate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Sevelamer Carbonate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000176141","MMSL":"131538","NDDF":"007676","UNII":"9YCX42I8IU","VUID":"4027337","VANDF":"4024131","INN_ID":"7620","RXNORM":"214824","UMLSCUI":"C1721288","chemblId":"CHEMBL5314347","ChEMBL_ID":"CHEMBL1201799","KEGG_DRUG":"D06642","DRUGBANK_ID":"DB00658","PUBCHEM_CID":"11593706","SNOMEDCT_US":"329195003","MESH_DESCRIPTOR_UI":"D000069603"},"formularyStatus":[],"originalProduct":{"form":"POWDER, FOR SUSPENSION","route":"ORAL","company":"Genzyme Corporation","brandName":"Renvela","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2007-","companyName":"Genzyme","relationship":"Original Developer"},{"period":"2009","companyName":"Genzyme Europe Bv","relationship":"EMA Licensee"}],"publicationCount":142,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"originalDeveloper":"Genzyme","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":20,"_genericFilersChecked":true,"genericManufacturerList":["Amneal Pharms Co","Arthur Grp","Aurobindo Pharma","Bionpharma","Chartwell Rx","Dr Reddys","Epic Pharma Llc","Impax","Impax Labs Inc","Invagen Pharms","Lupin Ltd","Macleods Pharms Ltd","Micro Labs","Navinta Llc","Rising","Shandong Xinhua","Strides Pharma","Strides Pharma Intl","Torrent","Zydus Pharms"],"status":"approved","companyName":"Genzyme","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"2007","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2007-10-19T00:00:00.000Z","mah":"GENZYME","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2009-06-09T00:00:00.000Z","mah":"GENZYME EUROPE BV","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-09-29T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA206094"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-11-28T00:00:00.000Z","mah":"AMNEAL PHARMS CO","brand_name_local":null,"application_number":"ANDA207288"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-25T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA207624"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-10T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA206100"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-25T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA207291"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"88.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"regulatorySummaries":{"US_FDA_approval_31161":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"31161","summary_short":"The FDA granted marketing authorisation to MACLEODS PHARMS LTD for Renvela on 2024-04-10.","summary_long":"The FDA approved Renvela, a drug product, on 2024-04-10. The marketing authorisation holder is MACLEODS PHARMS LTD. The approval was granted through a standard expedited pathway. The indication approved is for labeling.","key_points":["Renvela was approved by the FDA on 2024-04-10.","The marketing authorisation holder is MACLEODS PHARMS LTD.","The approval was granted through a standard expedited pathway."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA206100"}],"generated_at":"2026-05-18T09:31:33.369Z"}},"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:58.002353+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}